Tags

Type your tag names separated by a space and hit enter

Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis.
Oncology (Williston Park) 2003; 17(9):1281-8O

Abstract

Mycosis fungoides is a low-grade lymphoproliferative disorder caused by CD4+ lymphocytes. It is the most common type of cutaneous T-cell lymphoma. Typically, neoplastic T cells localize to the skin and produce patches, plaques, tumors, or erythroderma. Diagnosis of early mycosis fungoides can be difficult due to the nonspecific nature of cutaneous and histologic findings. However, recent advances in the application of histologic criteria, coupled with molecular biology tools such as immunophenotyping and polymerase chain reaction, have improved diagnostic accuracy. Independent prognostic factors include the extent and nature of skin involvement, the presence of extracutaneous disease, blood involvement, age > or = 60 years, and lactate dehydrogenase elevation. Accordingly, patients with limited patches and/or plaques (stage IA or IIA) experience long-term survival comparable to that of matched controls. The median survival is 11 years for patients with extensive patch/plaque (stage IB or IIA), 3.2 years for those with cutaneous tumors (stage IIB), 4.6 years for those with erythroderma (stage III), 1.2 years for those with pathologic nodal involvement (stage IVA), and 0.9 years for those with visceral disease (stage IVB). Over time, mycosis fungoides may progress to Sézary syndrome or transform to large-cell histology.

Authors+Show Affiliations

Yale University School of Medicine, New Haven, Connecticut, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14569854

Citation

Smith, Benjamin D., and Lynn D. Wilson. "Management of Mycosis Fungoides. Part 1. Diagnosis, Staging, and Prognosis." Oncology (Williston Park, N.Y.), vol. 17, no. 9, 2003, pp. 1281-8.
Smith BD, Wilson LD. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis. Oncology (Williston Park, NY). 2003;17(9):1281-8.
Smith, B. D., & Wilson, L. D. (2003). Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis. Oncology (Williston Park, N.Y.), 17(9), pp. 1281-8.
Smith BD, Wilson LD. Management of Mycosis Fungoides. Part 1. Diagnosis, Staging, and Prognosis. Oncology (Williston Park, NY). 2003;17(9):1281-8. PubMed PMID: 14569854.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis. AU - Smith,Benjamin D, AU - Wilson,Lynn D, PY - 2003/10/23/pubmed PY - 2004/2/5/medline PY - 2003/10/23/entrez SP - 1281 EP - 8 JF - Oncology (Williston Park, N.Y.) JO - Oncology (Williston Park, N.Y.) VL - 17 IS - 9 N2 - Mycosis fungoides is a low-grade lymphoproliferative disorder caused by CD4+ lymphocytes. It is the most common type of cutaneous T-cell lymphoma. Typically, neoplastic T cells localize to the skin and produce patches, plaques, tumors, or erythroderma. Diagnosis of early mycosis fungoides can be difficult due to the nonspecific nature of cutaneous and histologic findings. However, recent advances in the application of histologic criteria, coupled with molecular biology tools such as immunophenotyping and polymerase chain reaction, have improved diagnostic accuracy. Independent prognostic factors include the extent and nature of skin involvement, the presence of extracutaneous disease, blood involvement, age > or = 60 years, and lactate dehydrogenase elevation. Accordingly, patients with limited patches and/or plaques (stage IA or IIA) experience long-term survival comparable to that of matched controls. The median survival is 11 years for patients with extensive patch/plaque (stage IB or IIA), 3.2 years for those with cutaneous tumors (stage IIB), 4.6 years for those with erythroderma (stage III), 1.2 years for those with pathologic nodal involvement (stage IVA), and 0.9 years for those with visceral disease (stage IVB). Over time, mycosis fungoides may progress to Sézary syndrome or transform to large-cell histology. SN - 0890-9091 UR - https://www.unboundmedicine.com/medline/citation/14569854/Management_of_mycosis_fungoides__Part_1__Diagnosis_staging_and_prognosis_ L2 - http://www.diseaseinfosearch.org/result/5014 DB - PRIME DP - Unbound Medicine ER -